Clearstead Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Clearstead Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	3,940 +2	+0.1%	+$603	0.16%	67
2026 Q1	$1.3M	Sell	3,938 -28	-0.7%	-$9.53K	0.21%	63
2025 Q4	$1.58M	Sell	3,966 -28	-0.7%	-$12.4K	0.25%	59
2025 Q3	$1.82M	Sell	3,994 -286	-7%	-$116K	0.31%	53
2025 Q2	$1.4M	Buy	4,280 +288	+7%	+$79.7K	0.26%	59
2025 Q1	$1.08M	Buy	3,992 +11	+0.3%	+$2.83K	0.24%	65
2024 Q4	$937K	Hold	3,981	–	–	0.2%	67
2024 Q3	$1.09M	Hold	3,981	–	–	0.26%	58
2024 Q2	$967K	Hold	3,981	–	–	0.24%	58
2024 Q1	$595K	Hold	3,981	–	–	0.16%	73
2023 Q4	$762K	Hold	3,981	–	–	0.21%	71
2023 Q3	$705K	Hold	3,981	–	–	0.23%	68
2023 Q2	$766K	Hold	3,981	–	–	0.25%	66
2023 Q1	$797K	Hold	3,981	–	–	0.25%	67
2022 Q4	$946K	Hold	3,981	–	–	0.32%	56
2022 Q3	$796K	Buy	3,981 +3,000	+306%	+$572K	0.28%	60
2022 Q2	$143K	Hold	981	–	–	0.11%	88
2022 Q1	$160K	Sell	981 -142	-13%	-$21.6K	0.1%	94
2021 Q4	$190K	Hold	1,123	–	–	0.11%	91
2021 Q3	$212K	Buy	+1,123	New	+$211K	0.13%	87

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Trust's ALNY Position: Q2 2026 in Review

Clearstead Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 0.05% in Q2 2026, buying an estimated $603 and bringing the position to 3,940 shares worth $1.19M. The position accounts for 0.16% of the portfolio, ranked #67.

Clearstead Trust first reported a position in ALNY in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.82M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Clearstead Trust held 3,940 shares of Alnylam Pharmaceuticals worth $1.19M as of Q2 2026.
Clearstead Trust bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
Alnylam Pharmaceuticals made up 0.16% of Clearstead Trust's portfolio in Q2 2026, its #67 holding.
Clearstead Trust first reported a position in Alnylam Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
Clearstead Trust's Alnylam Pharmaceuticals position peaked at $1.82M in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Clearstead Trust's 13F filing for Q2 2026, filed 6 Aug 2026.